Overview

A Study to Assess the Abuse Potential of Intranasal Cebranopadol

Status:
COMPLETED

Trial end date:
2024-11-06

Target enrollment:

Participant gender:

Summary

The purpose of this study to Assess the Abuse Potential of Intranasal Cebranopadol Compared to Oxycodone and Placebo in Healthy, Nondependent Recreational Opioid Users.

Phase:

PHASE1

Details

Lead Sponsor:

Tris Pharma, Inc.

Treatments:

6'-fluoro-4',9'-dihydro-N,N-dimethyl-4-phenylspiro(cyclohexane-1,1'(3'H)-pyrano(3,4-b)indol)-4-amine